Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel–carboplatin therapy responded to autologous formalin-fixed tumor vaccine
Clin Case Rep. 2015 Oct;3(10):823-6. doi: 10.1002/ccr3.353. Epub 2015 Sep 2.
Chen JT 1 & Ohno T 2
1. Jui-Tung Chen Clinic, Akasaka 2-13-5-B1F, Minato-Ku, Tokyo 107-0052, Japan. (E-mail: chin-cl@m.jcnnet.jp)
2. Cell-Medicine, Inc., Sengen 2-1-6, Tsukuba Science City, Ibaraki 305-0047, Japan
Key Clinical Message:
Paclitaxel–carboplatin therapy (TC) usually controls primary peritoneal serous carcinoma (PPSC) but not recurrent disease. In this case, PPSC recurred after three courses of TC, responded dramatically to additional autologous formalin-fixed tumor vaccine (AFTV), and resulted in prolonged, progression-free survival without visible lesions detected by positron emission tomography–computed tomography.